CD73 is associated with poor prognosis in HNSCC-Reference-Cited by-同舟云学术

CD73 is associated with poor prognosis in HNSCC

Published:2016-08-20 Issue:38 Volume:7 Page:61690-61702
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Ren Zhen-Hu¹²,Lin Cheng-Zhong¹²,Cao Wei¹²,Yang Rong¹²,Lu Wei¹²,Liu Zhe-Qi¹²,Chen Yi-Ming¹²,Yang Xi¹²,Tian Zhen³,Wang Li-Zhen³,Li Jiang³,Wang Xu¹²,Chen Wan-Tao¹²,Ji Tong¹²,Zhang Chen-Ping¹²

Affiliation:

1. Department of Oral Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

2. Shanghai Research Institute of Stomatology and Shanghai Key Laboratory of Stomatology, Shanghai 200011, China

3. Department of Oral Pathology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of CD73 in predicting the response to immunotherapy in head and neck cancer patients;Pathology - Research and Practice;2024-08

2. CD73 Is an Immunometabolic Biomarker of Poor Prognosis in Patients With Primary Cutaneous Squamous Cell Carcinoma and Hematologic Malignancy;Dermatologic Surgery;2024-07-08

3. The immunomodulatory ballet of tumour‐derived extracellular vesicles and neutrophils orchestrating the dynamic CD73/PD‐L1 pathway in cancer;Journal of Extracellular Vesicles;2024-07

4. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours;Nature Reviews Cancer;2024-06-12

5. Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion;Biology;2024-04-28